diabetes drugs

Study: New Diabetes Drug Class Reduces Heart DeathsNew class of glucose-lowering agents lowers hospitalization and death rates even in Type 2 patients without heart disease.
Once-daily diabetes drug approvedFDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes.
New diabetes medications help address linked diseasesExperts share updates on new diabetes medications, and provide an overview of what’s coming.
Watch list 2017: Top therapeutic areas
Watch list 2017: Top therapeutic areasFind out about the latest treatment and drug pipeline developments
New diabetes combo drug available soonA new combination drug for type 2 diabetes will available in the US in the coming months.
New drug indication could net more than $1 billionFDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.
Invokamet extended-release approved for diabetesFDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The original Invokamet was approved by FDA in 2014.
New diabetes drug up against leading brandsFDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).
FDA issues a new warning about popular diabetes drugFDA approves a new indication, then issues strengthened warning about possible effects.
New diabetes drug enters competitive marketIn a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.